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Hemangiopericytoma (HPC) is a rare form of vascular tumour. It consists of extensive 
proliferation of pericapillary cells (pericytes). The most common locations are the head 
and neck, lower extremities and retroperitoneum. HPC can be benign or malignant. 
Malignant HPC can metastasize to other areas of the body, usually to the lungs. Up to 5-
10% HPCs present in childhood and 5-40% occur in the 1st year of life. We report a fetal 
case of HPC presenting as an ultrasound finding of a forehead mass. CASE: The proband 
was a 23y P1 Caucasian woman and her husband was 22y and of same descent. The 
couple was healthy and non-consanguineous. Early fetal ultrasounds were normal. IPS 
was negative. Ultrasound at 19w showed bilateral pelviectasis. A follow-up ultrasound at 
32w confirmed the pelviectasis, and also showed a midline mass over the forehead just 
above the nasal bridge, with slightly amorphous content measuring 4.1 x 4.0 x 3.1 cm. 
The mass did not appear to penetrate the scalp or skull and no gross abnormalities in the 
brain were seen. The nose and eyes appeared normal. The findings were confirmed by 
fetal MRI. The couple decided to continue the pregnancy. Delivery was at 38.8w via CS 
and was uncomplicated. The birth growth parameters were all normal. The APGAR 
scores were 9(1) and 10(5). A pedunculated tumor with a large base which measured 4 
cm, originating in the right side of the forehead was noted. There were areas of necrosis 
and excoriation over the skin and no thrill over the tumor. The baby was otherwise not 
dysmorphic. Complete surgical resection was performed and histopathology was 
consistent with HPC. DISCUSSION: Congenital HPC behaves in a distinct manner and 
has excellent prognosis. Etiologically, congenital HPC may arise from a pluripotent cell 
capable of differentiating into smooth muscle cells, pericytes and retains its capabilities 
to differentiate into more mature cells, resembling infantile myofibromatosis. A single 
entity called composite myofibromatosis has been proposed. From our knowledge, this 
case is the 7th case of congenital/ infantile HPC reported in the literature. Previous cases 
affect the lip, nose, temporal bone, meninges, the cerebrum and the neck region. 
Complete surgical resection is the ideal treatment of choice. Since excellent response to 
chemotherapy has been seen, extensive surgical excision and radiotherapy are to be 
avoided. Long-term follow-up is recommended as relapse may occur late. 
